Conduit Pharmaceuticals Inc. (CDT)

Compare

0.6999

-0.0470

(-6.52%)

As of 12:17:26 PM EDT. Market Open.

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that the United States Patent and Trademark Office (USPTO) has granted the compo

GlobeNewswire 3 days ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth. NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 19, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit” or the “Company”) today provides an R&D update on the development progress of pipeline asse

GlobeNewswire 15 days ago

CDT
-6.52%
CDTTW
Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now?

We recently compiled a list of the 10 Best Micro Cap Stocks to Buy Now. In this article, we are going to take a look at where Conduit Pharmaceuticals Inc. (NASDAQ:CDT) stands against the other micro cap stocks. Just as we overlook loose change, micro-cap stocks are often ignored for larger, more dominant enterprises. Investors trying […]

Insider Monkey 27 days ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 06, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) announces that, on February 11, 2025, the Company presented its plan of compliance to The Nasdaq Stock Market LLC ("Nasdaq”) Hearing Panel (the "Panel”) and requested an extension of time to achieve compliance with Nasdaq Listing Rules 5450(a)(1), 5450(b)(2&3)(C) and 5450(b)(2)(A), the Minimum Bid Price ("Bid Price”),

GlobeNewswire 28 days ago

CDT
-6.52%
CDTTW
Conduit Progresses Phase II of its AI Initiative with Sarborg

Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug developmentSarborg delivers a prototype AI-product to Conduit’s Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), is pleased to announce the completion of the initial milestones in Phase II of its strategic collaboration with AI and Cy

GlobeNewswire last month

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River’s immunology expertise to refine study parameters and improve probability of successful Phase II clinical trial outcomes.The study aims to accelerate the development of AZD1656 (and its derivatives), for autoimmune disorders, with a focus on Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN). NAPLES, Fla. and CAMBRIDGE, United Kingdom,

GlobeNewswire last month

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announces the repayment of its $600,000 promissory note (the “Note”) to Nirland Limited (“Nirland”) and provided an update on the conversion of its Senior Secured Promissory Note (the “Senior Note”) with Nirland. On February 7, 2025, Conduit repaid the final balance of the Note in full, satisfying all obligations under the agreement. The Not

GlobeNewswire last month

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to enhance efficiency, decision-making, and operational agility of its current and future portfolio NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announces the successful completi

GlobeNewswire last month

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence

Conduit is planning how to effectively integrate an advanced platform-driven approach powered by artificial intelligence and cybernetics to expedite drug development, while continuing to advance its portfolio of proprietary assets to clinic. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today is pleased to announce the completion of the first phase of its strategic collaboration with Sarborg

GlobeNewswire 2 months ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-100 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Annual Meeting of Stockh

GlobeNewswire 2 months ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline

Award-winning Agility Life Sciences brings a proven track record in drug formulation for a number of pharmaceutical and biotechnology clients. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced that it has entered into a strategic services agreement with formulation development CDMO Agility Life Sciences (“Agility”) to develop new solid oral-dosage form products of its autoimmune p

GlobeNewswire 2 months ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics

Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and clinical trial monitoring. This innovative approach aims to reduce human error, cut costs, and improve efficiency, positioning Conduit for success across its current and future portfolio. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq:

GlobeNewswire 3 months ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

Approval of composition of matter patent in key jurisdiction underscores the Company’s commitment to maximize future out-licensing valueNAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company’s lead asset, AZD1656, a Glucokinase Activator targ

GlobeNewswire 4 months ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound developme

GlobeNewswire 4 months ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals announces new addition to autoimmune pipeline

Conduit Pharmaceuticals (CDT) announces the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca targeting a broad spectrum of autoimmune disorders. The patent applications include a novel composition of matter filing for CDT1656, the newly introduced asset in Conduit’s portfolio. CDT1656 combines AZD1656 with a second compound whose mechanism of action plays a critical role in the progression of autoimmune

TipRanks 4 months ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline

Conduit Pharmaceuticals announces new addition to its autoimmune pipeline, underscored by composition of matter patent filing to strengthen its competitive position This new asset, CDT1656, combines AZD1656 with a second known-compound that has demonstrated immune-modulating effects across multiple autoimmune conditions, enhancing its therapeutic potentialThe addition of CDT1656 and the supporting composition of matter patent filing highlight Conduit’s commitment to building a robust asset portf

GlobeNewswire 4 months ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third parties. Conduit entered into a $2.65 million loan note with Nirland on A

GlobeNewswire 4 months ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024. Dr. David Tapolczay, Founder and CEO of Conduit, will give a virtual presentation available on-demand starting on September 9th at 7:00 am ET/12:00 pm BST. Dr. Tapolczay will also be available for in-person, one-on-one investor meet

GlobeNewswire 7 months ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656AZD1656, a HK-4 glucokinase activator initially developed by AstraZeneca for diabetes, is now being repurposed by Conduit for autoimmune disorders, leveraging its established safety profile and targeted immune-modulating effects SAN DIEGO and LONDON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: C

GlobeNewswire 7 months ago

CDT
-6.52%
CDTTW
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor AZD5904 targeting idiopathic male infertilityAssets have shown favorable preclinical and Phase I data. Conduit to initiate Phase II clinical trials SAN DIEGO and LONDON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”), today announced that the Co

GlobeNewswire 7 months ago

CDT
-6.52%
CDTTW

Performance Overview

Return	CDT	S&P 500 (^GSPC)
YTD	-89.86%	-6.99%
1-Year	-99.79%	+4.97%
3-Year	-99.93%	+20.34%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Conduit Pharmaceuticals Inc. (CDT)

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now?

Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

Conduit Progresses Phase II of its AI Initiative with Sarborg

Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model

Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note

Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline

Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Conduit Pharmaceuticals announces new addition to autoimmune pipeline

Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Performance Overview